Drug Profile

FID 022

Alternative Names: FID-022

Latest Information Update: 26 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Nov 2024 Fulgent Pharma plans a phase I trial for Solid tumors (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in April 2024 (IV) (NCT06694480)
03 May 2024 Preclinical trials in Colorectal cancer in USA (unspecified route), prior to May 2024
03 May 2024 Fulgent Pharma announces intention to submit IND application to the US FDA for Colorectal cancer by the end of 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com